<DOC>
	<DOCNO>NCT01627106</DOCNO>
	<brief_summary>This study compare vernakalant therapy amiodarone therapy acute management recent onset atrial fibrillation .</brief_summary>
	<brief_title>A Study Comparing Vernakalant Therapy Amiodarone Therapy Acute Management Recent Onset Atrial Fibrillation ( AF ) ( MK-6621-055 )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Symptomatic AF ( duration current episode â‰¤7 day ) , hemodynamically stable , participant condition time screening may result acute hospitalization If female reproductive potential , patient agrees remain abstinent use 2 acceptable method birth control time screen 30day followup . Weigh least 45 kg Receiving adequate anticoagulant therapy Hypersensitivity vernakalant amiodarone citric acid , sodium chloride , sodium hydroxide , iodine Severe aortic stenosis Systolic blood pressure &lt; 100 mmHg New York Heart Association ( NYHA ) Class III IV heart failure Severe bradycardia , sinus node dysfunction , second third degree heart block absence pacemaker Use IV rhythm control antiarrhythmic ( Class I III ) within 4 hour study drug administration Acute coronary syndrome ( include myocardial infarction ) within previous 30 day History thyroid dysfunction Severe acute respiratory failure cardiovascular collapse Participating another drug study receive investigational drug within 30 day prior enrollment Pregnant breastfeeding , expect conceive time screen 30day followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>